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Cancer is thought to be caused by the interaction between genetic susceptibility and environmental toxins. 
Based on the DNA changes in cells, proliferating cycle of tumor cells can be divided into 4 phases. Pre-
synthetic phase (Gap 1 phase or G1 phase). Cells chiefly make preparations for the synthesis of DNA. 
Synthetic phase (S phase). Cells are synthesizing their DNA. Post-synthetic phase (Gap 2 phases or G2 
phase). DNA duplication has been finished and they are equally divided to the two of future sub-cells. 
Mitosis phase (M Phase). Each cell is divided into two sub-cells. Some of these new cells enter the new 
proliferating cycle, the others become non-proliferating cells. G0 phase cells have proliferation ability but do 
not divide temporally. When proliferating cells are suffered heavy casualties, G0 phase cells will get into 
proliferating cycle and become the reasons of tumor recurrence.G0 phase cells are usually not sensitive to 
antineoplastic drugs, which is the important obstacle to tumor.chemotherapy. The antiproliferative activities 
of these compounds wee evaluated against a Cytotoxicity analysis of compounds against leukemia cell line -
K562 organism homo sapiens(human) organ bone – marrow, tissue - lymphoblast, disease – chronic 
myelogenous leukemia(CML) one human tumor cell lines(K562) by applying the MTT colorimetric assay. 
The 1, 3-disubstituted urea derivatives show good antiproliferative activity against human cancer cell lines 
(K562). The hydroxyl groups on the phenyl ring reduced the antiproliferative activities. 
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INTRODUCTION 
In the present study 1, 3-disubstituted urea derivatives 
(compounds A) were synthesized. The antiproliferative 
activities of this compound were evaluated against a 
panel of one human tumor cell lines (K562) by applying 
the MTT colorimetric assay. The series of 1,3-
disubstituted urea derivatives show good 
antiproliferative activity against human cancer cell lines 
(KB and K562) .The potent in vitro antiproliferative 
activity of these derivatives and their selectivity for 
quite important points for an anticancer drug candidate 
with fewer side effects. Structure activity relationships 
were also discussed based on the obtained experimental 
data. 2-amino-5-phenyl1, 3, 4-thiadiazolebearing 
different substituent were synthesized and evaluate their 
antiproliferative activities. The hydroxyl groups on the 
phenyl ring reduced the antiproliferative activities of 1, 
3-disubstituted urea derivatives. The OH groups could 
be responsible for a reduction in the permeability of the 
cell membrane. Generally, an aromatic ring on N-3 
seems to be in favor of enhancing the inhibitory activity, 
compounds introduced a nitro group substituent at C-3 
position on the aromatic ring approved to generally 
decrease activity. The compound has been characterized 
by elemental analysis IR, 1H NMR, Mass spectral data. 
 
METHOD 
Thionyl chloride, Dimethylformamide, Ethyl acetate, 
Dry pyridine, Ethanol, Benzaldehyde Chloro 
benzaldehyde, Nitrobenzaldehyde, Methoxy 
benzaldehyde. Human tumor cell lines (K562). 
Synthesis Compound 
(A) Aldehyde was dissolved in 25 ml of ethanol, and 
amine was added to the solution. The reaction mixture 
was refluxed for1 h. 
B) 0.05 mmol of NaBH4 was then added to the reaction 
solution slowly, and stirred under 50°C for 23 h. The 
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mixture was evaporated under vacuum, and dissolved in 
EtOAc (30 ml). The solution was washed with 20 ml 
water twice, dried over anhydrous sodium sulfate, and 
evaporated. Purification by silica gel afforded pure 
products.  
(C) The mixture of CH2Cl2 (15 ml) dry DMF (3 ml, 40 
mmol) and SOCl2 (7 ml, 0.10 mol) was stirred to reflux 
at 70°C for4 h and cooled. The solvents and excess 
SOCl2 were then removed under reduced pressure. The 
residue dissolved inCH2Cl2 (15 ml) was added to dry 
pyridine (4 ml)  
(D) and various amines (40 mmol). The reaction 
mixture was stirred at 50 to 60°c for 5 to 6 h, and then 
added to 20 ml ice-water, organic layer was separated, 
and the aqueous layer was extracted with ethyl acetate 
(2 to 10 ml). The organic layer was combined and 
washed with saturated NaHCO3, dried with anhydrous 
Na2SO4 for 0.5 h and concentrated under vacuum; 
ultimately the residue was purified by silica gel column 
(eluent EtOAc / petroleum ether, 1:2 - 2:1). 
Scheme for synthesis compound:- 
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Compound Structure Mol. Formula Mol. wt. Nature 
I 
S
N N
NH2
H  
5-phenyl-1,3,4-thiadiazol-2-amine 
C8H7N3S 177.2 Pink color crystal 
 
Tab-1 Synthesized amine compound 
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SYNTHESIS OF COMPOUND: 
STEP-1 
OH
                                           +                      
S
N N
NH2
H
 
        Benzaldehyde   
 
N
N
S
N
NH2 
5-(4-{[(E)-phenylmethylidene] amino} phenyl)-1, 3, 4-thiadiazol-2-amine 
STEP-2 
N
N
S
N
NH2        +  
NaBH4 
5-(4-{[(E)-phenylmethylidene] amino} phenyl)-1, 3, 4-thiadiazol-2-amine 
 
NH
N
S
N
NH2 
5-[4-(benzyl amino) phenyl]-1, 3, 4-thiadiazol-2-amine 
STEP-3 
             
NH
N
S
N
NH2            +  
Cl
S
ON
H
 
5-[4-(benzyl amino) phenyl]-1, 3, 4-thiadiazol-2-amine  N-[(E)-{[chloro (methylidene)-4-sulfanyl] oxy} 
methylidene] methanamine 
 
S
N N
N
O N
H
H
 
1, 1-dimethyl-3-phenyl-3-(5-phenyl-1, 3, 4-thiadiazol-2-yl) urea. 
 
 
5-phenyl-1, 3, 4-thiadiazol-2-amine Ethanol-reflux (1-hr.) 
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Code Compounds Mol. 
Formula 
Mol.Wt. Melting 
Point °C 
Crystals 
Nature 
% 
Yield 
S001 
 
S
N N
N
O N
H
H
 
1,1-dimethyl-3-phenyl-3-(5-phenyl-1,3,4-
thiadiazol-2-yl)urea 
C17H16N4OS 324.40014 215-217 
 
Brown 
color 
80% 
Tab 2 Synthesized Compound 
Physicochemical parameters: Compound: 
S
N N
N
O N
H
H
 
1,1-dimethyl-3-phenyl-3-(5-phenyl-1,3,4-thiadiazol-2-yl)urea 
Color – Yellowish Brown color; Odour  - odourless; Nature- Yellowish Brown crystal; MeltingPoing – 215 -217 °C 
 
S. No. Name of Solvents                            Solubility 
            Normal Tem.                  Hot.Tem. 
+ ± - + ± - 
1. Water       
2 Ethanol       
3. Methanol       
4. Chloroform       
5. Benzene       
6. Carbon Tetrachloride       
7. Ethyl acetate       
8. Pyridine       
9. Dimethyl formamide       
10. Dimethyl sulfoxide       
Tab 3. Solubility Profile 
 
TLC: 
Preparation of the plate: Chromatography a variety 
of coating materials is available, but silica gel is most 
frequently used. Slurry of the adsorbent (silica gel, 
cellulose powder, etc.) is spread uniformly over the 
plate by means of one of the commercial forms of 
spreader, the recommended thickness of adsorbent 
layer being 150-250 J.lm.After air-drying overnight, or 
oven-drying at 80-90 °C for about 30 minutes, it is 
ready for use. 
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Sample application: The origin line, to which the 
sample solution is applied, is usually located 2-2.5 cm 
from the bottom of the plate. 
Development of plates: Development is allowed to 
proceed until the solvent front has travelled the 
required distance (usually 10-15 cm), the plate is then 
removed from the chamber and the solvent front 
immediately marked with a pointed object. 
 
Compound Solvent system Ratio Rf Value 
SOO1 EtOAc:Petrolium ether 1:2 0.7 
Tab 4. Rf value of synthesized compound 
 
Elemental Detection of synthesized compound:  
 
Test Observation Result 
(1) 2ml sodium extract+3 drops of freshly prepared 
FeSo4+2-drops of NAOH and boil it then cool it 
+add 1 ml. dil.HCL+ FeCl3 solution. 
After some time green – blue ppt. 
obtained. 
Nitrogen present. 
 
Lassiagens Test-Sulphur Test 
(1)2ml.sodium extract+2ml.freshly prepared sodium 
nitrate. 
Violet color obtained then after some 
times it disappears in purple color. 
Sulphur present. 
Tab 5. Lassiagens Test-Nitrogen Test: 
 
 Test Observation Result 
(1)Take a small amount of sample+2ml. of NAOH 
solution and heat it then attach red litmas paper over 
the mouth of the test tube. 
Ammonia gas is evolved and Red 
litmus paper gets blue color 
Amide present. 
 
Tab 6. Amide Test 
 
Test Observation Result 
(1)small amount of sample in test tube +melt it then 
ammonia is evolved after some times when it 
resolidify dissolve it in 1ml. of dil.NAOH solution+2 
drops of dil. Copper sulphate solution 
Violet colors are developed then 
finally change in blue color. 
Urea present. 
Tab-7. Urea Test (Biuret Test) 
 
Test Observation Result 
 Take a small amount of sample in conc.HCl+2 ml. 
water  then cool in ice cold water + 2 ml.of dil. 
Sodium nitrate solution. 
Yellow ppt.obtained. Primary amines 
present. 
Tab-8. Amines Test 
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Peaks cm-1 Due to Probable Group 
1700.0 (Strong peak) C=O , stretching  Amide 
1250.2 (Strong peak) C-C , stretching Benzene 
768.00 (Strong peak) C-S  ,stretching  Thiourea 
3216.0 (Medium peak) N-H str.(asymmetric stretching) Primary Amide 
690.6(Weak peak) C-H ,  stretching   (Aromatic ring) 
1635.7(Weak peak) N=C, stretching Nitrate 
 
Tab 9. Infra Red / (KBr) (cm-1) spectral study of the synthesized compounds; SOO1- 1, 1-dimethyl-3-phenyl-3-(5-
phenyl-1, 3, 4-thiadiazol-2-yl) urea 
 
 
 
 
 
 
 
 
Fig.1 spectral study of the synthesized compounds 
 
 
 
Fig.2. NMR Proton- H1 Spectroscopy 
 
Fig.3  Mass spectroscopy 
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Determination of IC50 value:  
Assay         Percent Inhibition IC50  
Cell Line   K- 562 
Organism  Homo sapiens (human) 
Organ          bone marrow 
Tissue         lymphoblast 
Disease      chronic myelogenous 
leukemia (CML)  
Growth     Properties suspension  
Age             53 years 
Gender        Female. 
Table:-10. Cytotoxicity analysis of compounds against 
leukemia (K-562) 
 
 
Fig 4 X axis – concentration in micromole; Y axis- % 
growth inhibition 
 
RESULT & DISCUSSION 
Cells were incubated with different concentrations of 
the extract for 5 days in a 96 well plate, after which the 
live cells which did not take in stain and dead cells 
which took in stain were counted. For counting the cell 
suspension was mixed with an equal volume of trypan 
blue and was counted. Concentration that inhibited the 
growth of cells at 50% (IC50) was computed. 
Substances with low IC50 indicate potential for 
cytotoxicity. The synthesized compounds was 
confirmed by physic-chemical properties (melting 
point,TLC) and by IR spectral analysis. Sample-S001 
was found most potent compound for cytotoxic 
activity.(a) 1,1-dimethyl-3-phenyl-3-(5-phenyl-1,3,4-
thiadiazol-2-yl)urea. 
 
CONCLUSION 
The continuous cell line K-562 was established by 
Lozzio andLozzio from the pleural effusion of a 53-
year-old female with chronic myelogenous leukemia in 
terminal blast crises. [22609]The cell population has 
been characterized as highly undifferentiated and of the 
granulocytic series. [26059]Studies conducted by 
Anderson, et al., on the surface membrane properties led 
to the conclusion that the K-562 was a human 
erythroleukemia line. [26060]The K-562 cell line has 
attained widespread use as a highly sensitive in vitro 
target for the natural killer assay. Cells were incubated 
with different concentrations of the extract for 5 days in 
a 96 well plate, after which the live cells which did not 
take instain and dead cells which took in stain were 
counted. For counting, the cell suspension was mixed 
with an equal volume of trypan blue and counted. 
Concentration that inhibited the growth of cells at 50% 
(IC50) was computed. Substances with low IC50 
indicate potential for cytotoxicity. 
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